Cedars-Sinai Medical Center
New Bladder Cancer Molecular Classification Predicts Response to Common Immunotherapy
The new subtypes could help clinicians pick alternative therapies for patients unlikely to respond to Bacillus Calmette-Guérin treatment.
The assay combines microfluidics, gene expression, and digital PCR to provide information on whether a patient's cancer has metastasized.
The privately held company is coupling gene expression tests with analysis to produce clinical decision support as it expands beyond its historic focus on pharma.
Sudden Cardiac Death Risk Informed by Genome-Wide Polygenic Score for Heart Disease
In individuals with a history of coronary artery disease (CAD), a polygenic risk score for CAD showed promise for predicting the risk of sudden and/or arrhythmic death.
Cedars-Sinai, Tempus Partner on Molecular Database Initiative
The partners launched the Molecular Twin initiative to collect cancer patients' DNA, RNA, and protein information and use it to inform treatment and advance research.